HK1215929A1 - 冠毛素调节剂 - Google Patents

冠毛素调节剂 Download PDF

Info

Publication number
HK1215929A1
HK1215929A1 HK16103840.8A HK16103840A HK1215929A1 HK 1215929 A1 HK1215929 A1 HK 1215929A1 HK 16103840 A HK16103840 A HK 16103840A HK 1215929 A1 HK1215929 A1 HK 1215929A1
Authority
HK
Hong Kong
Prior art keywords
pappalysin
human
mammalian subject
polypeptide
stanniocalcin
Prior art date
Application number
HK16103840.8A
Other languages
English (en)
Chinese (zh)
Inventor
Claus Oxvig
Jakob Hauge Mikkelsen
Malene Runge JEPSEN
Original Assignee
奥胡斯大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 奥胡斯大学 filed Critical 奥胡斯大学
Publication of HK1215929A1 publication Critical patent/HK1215929A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24079—Pappalysin-1 (3.4.24.79)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK16103840.8A 2013-05-10 2014-05-12 冠毛素调节剂 HK1215929A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201370259 2013-05-10
DKPA201370259 2013-05-10
PCT/DK2014/050131 WO2014180485A2 (en) 2013-05-10 2014-05-12 Pappalysin regulator

Publications (1)

Publication Number Publication Date
HK1215929A1 true HK1215929A1 (zh) 2016-09-30

Family

ID=50943008

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103840.8A HK1215929A1 (zh) 2013-05-10 2014-05-12 冠毛素调节剂

Country Status (9)

Country Link
US (2) US20160151405A1 (https=)
EP (1) EP2994158A2 (https=)
JP (1) JP2016520583A (https=)
CN (1) CN105263510A (https=)
CA (1) CA2911933A1 (https=)
EA (1) EA201591894A1 (https=)
HK (1) HK1215929A1 (https=)
MX (1) MX2015015519A (https=)
WO (1) WO2014180485A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115835879A (zh) * 2020-06-30 2023-03-21 国立大学法人东北大学 Stat3磷酸化抑制剂、自身免疫性疾病和冠状病毒传染病的预防或治疗剂
TW202235618A (zh) * 2021-01-05 2022-09-16 美國馬友醫藥教育研究基金會 治療眼內壓相關疾患
WO2022270926A1 (ko) * 2021-06-22 2022-12-29 동아대학교 산학협력단 다양한 암의 진단, 전이 또는 예후 예측용 신규한 바이오마커 및 이의 용도
WO2024042220A1 (en) * 2022-08-25 2024-02-29 Aarhus Universitet Modulators of papp-a activity
TW202432584A (zh) 2022-11-15 2024-08-16 美商嘉來克生命科學有限責任公司 抗papp-a抗體及其使用方法
WO2026008015A1 (en) * 2024-07-05 2026-01-08 The University Of Hong Kong Stanniocalcin 2 (stc2) and derivatives as anti-diabetic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994103A (en) * 1995-06-02 1999-11-30 Human Genome Science, Inc. Human stanniocalcin-alpha
CA2387685A1 (en) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Stanniocalcin proteins and nucleic acids and methods based thereon
CA2389751A1 (en) 1999-11-01 2001-05-10 Curagen Corporation Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
US20100292303A1 (en) 2007-07-20 2010-11-18 Birrer Michael J Gene expression profile for predicting ovarian cancer patient survival
AU2009207645B2 (en) 2008-01-25 2014-11-13 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
WO2010020004A1 (en) * 2008-08-22 2010-02-25 Children's Medical Research Institute Compositions and methods for inhibition of adipogenesis and the treatment of obesity

Also Published As

Publication number Publication date
WO2014180485A3 (en) 2015-03-05
US20200261490A1 (en) 2020-08-20
JP2016520583A (ja) 2016-07-14
EP2994158A2 (en) 2016-03-16
WO2014180485A2 (en) 2014-11-13
US20160151405A1 (en) 2016-06-02
MX2015015519A (es) 2016-07-21
US11318158B2 (en) 2022-05-03
CN105263510A (zh) 2016-01-20
CA2911933A1 (en) 2014-11-13
EA201591894A1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
HK1215929A1 (zh) 冠毛素调节剂
MX2015008011A (es) Suplementos y sistemas de monitoreo para la dosificacion de los suplementos.
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
PH12017500680A1 (en) Compositions and methods of use for treating metabolic disorders
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
PH12018501903B1 (en) Methods of treating depression using orexin-2 receptor antagonists
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
EP4272839A3 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
IN2014KN02914A (https=)
SG10201901656WA (en) Nutritional compositions containing a peptide component with adiponectin stimulating properties and uses thereof
WO2014145236A3 (en) The use of sdf-1 to mitigate scar formation
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
WO2011132084A3 (en) Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
MX2016001686A (es) Composicion para el tratamiento contra el envejecimiento de la piel.
WO2014115033A3 (en) A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications
WO2013109190A3 (en) Cho-gmt recombinant protein expression
BR112014029308A2 (pt) um método de melhorar a função hepática
MX2017001737A (es) Vitamina b2 y sus usos.
WO2014115087A3 (en) A method for the preparation of recombinant human prothrombin and fibrinogen
WO2014122638A3 (en) Thalidomide and thalidomide analogues for the stimulation of stem cell factor
WO2014187964A3 (en) Novel treatment of metabolic diseases
Luk et al. Pathology, pathophysiology, and treatment strategies of endocrine disorders and their cardiac complications
MX364643B (es) USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.
MY197404A (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression